Hims and Hers misses revenue estimates as GLP-1 strategy shift pressures margins

Hims and Hers Health is back in focus after missing first-quarter revenue estimates and posting a surprise loss, even though the company raised its full-year revenue forecast. The key issue is not simply demand. The bigger story is the business model shift. Hims is moving away from lower-cost compounded GLP-1 weight-loss drugs and toward branded, FDA-approved treatments such as Wegovy through its partnership with Novo Nordisk. That shift may support long-term credibility, but it also brings margin pressure, legal costs, restructuring costs and a tougher path to profitability.

Winners

Branded obesity drug leaders

Hims shifting toward branded GLP-1 drugs strengthens the position of large pharmaceutical companies that own the approv ...